7 results
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
Diagnosis: Latent ... Treatment: Active ... HIV-infected patients should ... #TB #Diagnosis ... #Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
Diagnosis: Latent ... Treatment: Active ... HIV-infected patients should ... #TB #Diagnosis ... #Management #Treatment
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
IDSA - Clinical ... Individualized Treatment ... isolate DST result should ... #MDRTB #management ... #regimens #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
and molecular diagnostic ... should be initiated ... #TB #IDSA #Prevention ... #Treatment #management ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
IDSA Recommendations ... • Pap test should ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
Note: Active TB ... should be ruled ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Varicella Zoster Virus (VZV) Infections in HIV-AIDS
Pre-Exposure Prevention of VZV
IDSA Recommendations ... health-care provider diagnosis ... HIV-infected persons should ... #management #opportunistic ... infections #HIVAIDS #pharmacology